A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 1.7% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.Q3 Earnings & Sales Beat EstimatesJ&J’s third- ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Nov. 13:Flex Ltd. (FLEX) : This company which provides design, engineering, manufacturing, and supply chain services and solutions to original equipment manufacturers has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.4% over the last 60 days.Flex’s shares gained 27.3% over the last three months compared with the S&P 500’s advance of 6%. The company ...

In its upcoming report, Medtronic (MDT) is predicted by Wall Street analysts to post quarterly earnings of $1.31 per share, reflecting an increase of 4% compared to the same period last year. Revenues are forecasted to be $8.86 billion, representing a year-over-year increase of 5.4%.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial est ...

Appointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC DeviceHOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. (“Carmi Masha”), a leading Israeli medical device distributor, to market and sell Nexalin’s Gen-2 Console (“SYNC”), 15 mi ...

Key Takeaways Teleflex's Q3 adjusted EPS rose 5.2% to $3.67, beating consensus by 8.6%. TFX's net revenues jumped 19.4% to $913 million, surpassing estimates across key segments. Despite solid results, Teleflex lowered 2025 guidance, weighing on investor sentiment. Teleflex Incorporated (TFX) posted third-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $3.67, up 5.2% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 8.6%.GAAP loss per share wa ...

New York, New York--(Newsfile Corp. - November 13, 2025) - If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE: INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/inspire-medical-systems-inc-lawsuit-submission-form?prid=177137&wire=5&utm_campaign=5or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareho ...

RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA, non-invasive blood sensor, toward regulatory submission and future commercialization. Based on the clinical trial results and ongoing lab tests, showing between 95% to 99% accuracy across measured parameters, Inspira is ...

RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the completion of the clinical study for its HYLA,  non-invasive blood sensor, toward regulatory submission and future commercialization.Based on the clinical trial results and ongoing lab tests, showing between 95% to 99% accuracy across measured parameters, Inspira is ...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

New York, New York--(Newsfile Corp. - November 13, 2025) - If you suffered a loss on your Baxter International, Inc. (NYSE: BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=177135&wire=5&utm_campaign=8or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder ad ...